Peter Downie

Head of Unit

Monash Health
Country flagAustralia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Germline predisposition has a significant role in paediatric cancer. However, the optimal approach to identifying cancer-causing germline pathogenic variants (GPV) in children, and even the prevalence of GPV among children with cancer, remain unclear. Here we report our findings from a comprehensive survey of GPV in 496 children with poor-prognosis cancer. By integrating tumour and germline molecular profiling we identified GPV in 15.5% of patients, 48.1% of whom had not met clinical genetic testing criteria. Although the cancer type was outside the recognised phenotypic spectrum for 43.7% of reported GPV, 63.2% of these were clinically actionable for cancer risk. Integrated germline-tumour analysis increased the GPV detection rate by 8.5%, and informed germline interpretation in 14.3% of patients with GPV, highlighting the value of integrated analyses. Our findings establish the benefit of broad integrated tumour-germline screening, over phenotype-guided testing, to detect GPV in children with poor prognosis cancers.

Year:

2024

Background Concerns about side effects and treatment interactions and delays may contribute to COVID-19 vaccine hesitancy amongst cancer patients. In the large prospective SerOzNET study of COVID-19 vaccine response in children and adults with cancer, vaccine beliefs, physician- and participant-reported adverse events (AE), treatment interruptions and quality of life (QoL) were studied. Methods The Australian experience with COVID-19 gave a unique opportunity to study vaccination response in an infection- and vaccine-naïve cancer population. Patients with current or recent solid or hematological malignancy, aged five and over, had serial assessments prior to and following multiple SARS-CoV-2 vaccinations. Electronic surveys were administered at baseline and after first, second and third doses to collect vaccine beliefs (Oxford Confidence and Complacency Scale), patient-reported toxicity and QoL (QLQC30 or PedsQL). Detailed toxicity data were collected at clinic visits and from medical records. Results A total of 1385 vaccination doses were administered (93% BNT162b2), with at least 1 dose received by 499 patients, of whom only seven had known prior COVID-19 infection. Vaccine related beliefs were generally positive. There were no vaccine-related interruptions to cancer therapy. AE occurred in 95% of recipients, with the highest ranked severity being mild in 36% and moderate, severe or serious in 31%, 19% and 6% respectively. QoL showed no significant deterioration post-vaccination. Conclusion This robust dataset provides evidence regarding safety and tolerance of SARS-CoV-2 vaccination in adults and children with cancer. Patients and families can be reassured that rates of AEs are comparable to the general population and do not impact delivery of cancer therapy or QoL.

Year:

2024

Year:

2023

Collaborators (13)

Jordan R Hansford

Oncologist

University of Melbourne

AUSTRALIA
View details

Eva Segelov

MONASH UNIVERSITY

AUSTRALIA
View details

David Ziegler

Professor

University of New South Wales

AUSTRALIA
View details

Paul Ekert

Group Leader, Translational Tumour Biology

Children's Cancer Institute Australia

AUSTRALIA
View details

Nicholas Gottardo

University of Western Australia

AUSTRALIA
View details

Stephen Opat

Monash Health

AUSTRALIA
View details

Mark Cowley

Conjoint Professor

University of New South Wales

AUSTRALIA
View details

Vanessa Tyrrell

Co-Head of Division - Peronalised Medicine

Children's Cancer Institute Australia

AUSTRALIA
View details

Andrew Moore

Associate Professor

University of Queensland

AUSTRALIA
View details

Vivienne Milch

Professorial Fellow

Flinders University

AUSTRALIA
View details

Wayne Nicholls

Clinical Director and Associate Professor

University of Queensland

AUSTRALIA
View details

Chelsea Mayoh

Children's Cancer Institute Australia

AUSTRALIA
View details

Marion Mateos

University of New South Wales

AUSTRALIA
View details